Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative

Published:2019-04 Issue:5 Volume:46 Page:465-474
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Han Xuhua¹,Li Fang¹,Wen Zhou¹²,Ma Yuehui³,Wang Lei¹⁴^ORCID,Cheng Zeneng¹

Affiliation:

1. School of Pharmaceutical Sciences Central South University Changsha Hunan China

2. HunanHuize Bio‐pharmaceutical Co., Ltd Changsha Hunan China

3. Hunan Taixin Pharmaceutical Technology Co., Ltd Changsha Hunan China

4. School of Life Sciences Central South University Changsha Hunan China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13078

Reference26 articles.

1. Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications

2. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study

3. New renal drug development to face chronic renal disease

4. Mechanisms of fibrosis: therapeutic translation for fibrotic disease

5. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mefunidone alleviates silica-induced inflammation and fibrosis by inhibiting the TLR4-NF-κB/MAPK pathway and attenuating pyroptosis in murine macrophages;Biomedicine & Pharmacotherapy;2024-09

2. A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects;Frontiers in Pharmacology;2024-06-12

3. Protective effects of mefunidone on ischemia-reperfusion injury/Folic acid-induced acute kidney injury;Frontiers in Pharmacology;2022-11-23

4. Preclinical metabolic characterization of mefunidone, a novel anti-renal fibrosis drug;Life Sciences;2021-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3